000 02294cam  2200349zi 4500
0019.898414
003CaOODSP
00520221107174832
006m     o  d f      
007cr |||||||||||
008210408t20212021onc     ob   f00| 0 eng d
020 |a9780660383286
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH164-318/2021E-PDF
24500|aGuidance on amendments to the Food and Drug Regulations for drugs for use in relation to COVID-19.
264 1|a[Ottawa] : |bHealth Canada = Santé Canada, |c2021.
264 4|c©2021
300 |a1 online resource (iv, 32 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aIssued also in French under title: Lignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19.
504 |aIncludes bibliographical references (pages 30-31).
520 |a"This guidance applies to sponsors of new COVID-19 drug submissions as well as sponsors seeking a Notice of Compliance (NOC) for COVID-19 drugs that received temporary authorization under the Interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19 (ISAD IO). It also applies to new COVID-19 drug establishment licences under the Food and Drug Regulations. This document will help manufacturers prepare a submission for a Notice of Compliance for a COVID-19 drug under the Regulations. It also outlines the process for meeting the post-market regulatory requirements"--page 1.
650 0|aCOVID-19 Pandemic, 2020-|xHealth aspects|zCanada.
650 0|aPharmaceutical policy|zCanada.
7101 |aCanada. |bHealth Canada, |eissuing body.
77508|tLignes directrices sur les modifications apportées au Règlement sur les aliments et drogues pour les médicaments contre la COVID-19.|w(CaOODSP)9.898415
85640|qPDF|s1.22 MB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H164-318-2021-eng.pdf
8564 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/food-drug-regulations-amendments-covid-19.html